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Pyclooxygenase-2 Inhibitors Enhance
hear Stress-Induced Platelet Aggregation
iet Borgdorff, PHD, Geert Jan Tangelder, MD, PHD, Walter J. Paulus, MD, PHD
msterdam, the Netherlands
OBJECTIVES We aimed to investigate the effect of parecoxib, a selective cyclooxygenase-2 (COX-2)
inhibitor, on in vivo shear stress-induced platelet aggregation in a rat model of arterial bypass
with focal narrowing.
BACKGROUND Long-term use of COX-2 inhibitors is associated with increased incidence of adverse
cardiovascular events, especially in patients with a history of cardiovascular disease. These
patients are at risk for thrombotic occlusion of arterial stenoses initiated by shear stress-
induced platelet aggregation.
METHODS To mimic the combination of a tight arterial stenosis and high shear stress in rats, an
extracorporeal shunt from carotid to femoral artery was compressed by the rollers of a pump.
Platelet aggregation was continuously measured by a photometric detector in the shunt.
RESULTS Pretreatment with parecoxib (20 mg/kg) almost doubled shear stress-induced platelet
aggregation (188% vs. 100% in control subjects, p  0.0003). This was accompanied by a fall
in plasma 6-keto-prostaglandin F1 from 100  25 pg/ml to 36  11 pg/ml (p  0.0001).
Enhanced platelet aggregation was also observed with high-dose aspirin (150 mg/kg) (146%;
p  0.02) but not with low-dose aspirin (25 mg/kg), which reduced aggregation (68%; p 
0.01). The effect of parecoxib was neutralized by low-dose (1 mg/kg) clopidogrel (from 188%
to 92%; p  0.0001), but not by low-dose aspirin (from 188% to 177%; p  NS).
CONCLUSIONS In the presence of an arterial stenosis, COX-2 inhibitors enhance shear stress-induced platelet
aggregation. This enhancement was prevented by low-dose clopidogrel but not by low-dose
aspirin. Clopidogrel might therefore allow COX-2 inhibitors to be used without raising risk
of thrombotic occlusion. (J Am Coll Cardiol 2006;48:817–23) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.053College of Cardiology Foundation
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sse of selective cyclooxygenase-2 (COX-2) inhibitors has
een associated with increased risk of serious cardiovascular
arm (1–3). Excess death, myocardial infarction, or stroke
mong users of COX-2 inhibitors arose mainly from pa-
ients with pre-existing cardiovascular risk (1,4,5). This
uggests that new cardiovascular events during COX-2
nhibition result from destabilization of atheromatous
laques (6) or from thrombotic occlusion of pre-existing
rterial stenoses. Tight arterial stenoses are prone to throm-
otic occlusion because of the presence of elevated shear
tress, which promotes platelet aggregation. Because
OX-2 inhibitors block the basal production of prostacyclin
PGI2) (7–9) and because PGI2 is a strong inhibitor of
latelet aggregation (10), COX-2 inhibitors could reinforce
hear stress-induced platelet aggregation. So far, enhanced
latelet aggregation after long-term use of COX-2 inhibi-
ors has not been observed (9). These investigators, how-
ver, used in vitro aggregometry, which might have failed to
etect an effect of PGI2-inhibition on platelet aggregation
ecause the half-life of PGI2 does not exceed 3 min (11).
The present study therefore investigated the effect of
OX-2 inhibitors on in vivo platelet aggregation in a
ecently developed rat model of arterial bypass with high
hear stress (12,13). This model offers the advantage of a
ontinuous in vivo assessment of platelet aggregation and of
From the Institute for Cardiovascular Research, Vrije Universiteit Medical Center,
msterdam, the Netherlands.a
Manuscript received December 13, 2005; revised manuscript received March 17,
006, accepted March 22, 2006.ownstream vascular resistance and allows for detection of
uppressed platelet aggregation by endogenous PGI2. The
ffect of selective COX-2 inhibitors on platelet aggregation
as also compared with that of high- or low-dose aspirin. In
ddition, the present study investigated whether the effect of
OX-2 inhibitors on platelet aggregation could be neutralized
y co-administration of low-dose aspirin or of the adenosine
iphosphate (ADP) receptor antagonist clopidogrel.
ETHODS
detailed description of the experimental set-up has
reviously been published (12). In short, Wistar rats (330 to
50 g) were anesthetized with ketamine (60 mg/kg intra-
uscularly) and pentobarbital (35 mg/kg intraperitoneally,
ollowed by 0.16 to 0.23 mg/kg/min intravenously), venti-
ated, and heparinized with 800 IU/kg. In rats, a dose of 800
U/kg is needed to prevent clot formation in the extracor-
oreal system. Saline was infused throughout the experi-
ent at a rate of 0.016 ml/min. Body temperature was kept
t 37.5°C. All animal handling was in compliance with the
Guide for the Care and Use of Laboratory Animals”
National Institutes of Health publication No. 85-23, re-
ised 1985).
An extracorporeal shunt (medical grade polyvinyl chlo-
ide tubing, 1.5-mm inside diameter, 65 cm long), primed
ith a colloid osmotic solution (Gelofusine, Braun, Mel-
ungen, Germany), was placed between the proximal part of
carotid artery and distal part of a femoral artery. To
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COX-2 Inhibitors Enhance Platelet Aggregation August 15, 2006:817–23revent platelet activation by the contact or complement
ystem, all tubing was coated with albumin. Part of the
hunt consisted of a peristaltic polyvinyl chloride tube
Gilson, Viliers Le Bel, France) that was loosely positioned
n a roller pump. To switch from autoperfusion to pump
erfusion, the tube was gradually compressed by tightening
he rollers of the pump with a calibrated screw until flow
topped. Then the pump was started, and its speed was
djusted to restore flow to the original level, as measured
ith an inline flow probe (1N, Transonic Systems Inc.,
thaca, New York).
Platelet aggregation downstream of the pump was con-
inuously measured with a photometric device that detects
n increase in light transmission when platelet aggregates
ass through a glass capillary. Once the output signal of the
hotometric device exceeded a threshold, the signal was
onverted to a uniform spike and counted (Fig. 1). Platelet
ggregation was quantified by the amount (n) of platelet
ggregates (PA) per milliliter of shunted blood during a
0-min pump perfusion run and expressed as nPA/ml.
Although there is no aggregation during spontaneous
ow, start of the pump immediately elicits strong platelet
ggregation that is maximal during the first 3 to 5 min
efore leveling off to a lower value that persists as long as
ump perfusion continues. This platelet aggregation is
nitiated by the time-varying shear stress resulting from
ompression of the tube by the rollers and does not result
rom plasticizers or factors released from the albumin-
oating nor from ADP released from damaged erythrocytes,
ecause there is no detectable hemolysis (13). The involve-
Abbreviations and Acronyms
ADP  adenosine diphosphate
COX-2  cyclooxygenase-2
GP  glycoprotein
nPA  amount of platelet aggregates per milliliter of
shunted blood
P2Y12  5=-diphosphate receptors
PGF  prostaglandin F
PGI2  prostacyclin
vWf  von Willebrand factor
igure 1. (Left) Experimental set-up with roller pump and photometric d
arotid and femoral artery. (Right) Aggregate detection (upper recording) and
uring autoperfusion and aggregation after the pump is switched on.ent of shear stress in this model has been demonstrated by
he use of aurintricarboxylic acid, which inhibits shear-
nduced platelet aggregation and blocked platelet aggrega-
ion in this model (14). Although platelet aggregation in
his model can already be elicited, albeit less intensely, by a
ingle and partial occlusion of the tube, the present study
sed a pump run to have a continuous and protracted
ssessment of platelet aggregation. At the tightening of the
ump rollers used in the present experiments, shear stress
xceeded by far 100 dynes/cm2, the level known to elicit
latelet aggregation (13). The calibrated tightening of the
ump rollers guaranteed equivalent amounts of shear stress
n each experiment.
The vascular bed of the cannulated femoral artery was
sed as a “bioassay” for the circulatory effects of upstream
latelet aggregation. To this end, pulsatile femoral artery
ressure and flow were averaged and femoral resistance was
ontinuously calculated as the ratio of mean pressure over
ow (15). Femoral pressure was measured via a T-piece at
he distal shunt insertion site. The pressure-drop over the
hunt was 5 to 8 mm Hg.
Plasma PGI2 levels were studied by measuring its stabile
etabolite 6-keto-prostaglandin F (PGF)1 with an EIA
iotrak system (Amersham Biosciences, Piscataway, New
ersey). The detection limit was 3.0 pg/ml. Basal control
alues were determined in arterial blood from untreated
nimals, whereas the effect of COX-2 inhibition was mea-
ured in experimental animals, 1 h after receiving parecoxib,
ust before the experiment.
rugs. The following selective COX-2 inhibitors were
sed: parecoxib, which is the injectable form of valdecoxib
20 mg/kg; Dynastat, Pfizer, New York), and NS-398 (15
g/kg; Sigma, St. Louis, Missouri). Clopidogrel (Sanofi-
ynthelabo, Toulouse, France) was used to specifically block
latelet adenosine 5=-diphosphate receptors (P2Y12). Pare-
oxib and clopidogrel were dissolved in saline and admin-
stered intravenously 1 h before the experiment. The NS-
98 was given orally, 2 h before the experiment.
Aspirin (Aspegic, Lorex Synthelabo, Maarssen, the
etherlands) was injected as a low dose (25 mg/kg) intra-
eritoneally on the day before the experiment or as a high
which measures platelet aggregation in the extracorporeal shunt betweenevice,
its quantification (lower recording). Note absence of platelet aggregation
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August 15, 2006:817–23 COX-2 Inhibitors Enhance Platelet Aggregationose (150 mg/kg) intravenously 1 h before the start of pump
erfusion. The lower dose has been shown to block rat
latelet thromboxane (TXA2) formation for several days
16) but to block endothelial PGI2 formation for 6 h only
17). It is equivalent to the clinically used low-dose acetyl-
alicylic acid (ASA) in the prophylaxis of myocardial infarc-
ion. Aspirin (150 mg/kg) was used to non-selectively block
he production of both platelet thromboxane (COX-1) and
ndothelial PGI2 (COX-2) in the rat (17).
tatistics. Values in the text are expressed as mean  SD,
nd in the figures as mean  SEM. The nPA/ml values
nder different conditions were compared with one-way
nalysis of variance followed by Dunnett’s Multiple Com-
arison Test. Time series data of vascular resistance under
ifferent conditions were analyzed with two-way analysis of
ariance for repeated measurements. Differences were consid-
red statistically significant if p  0.05.
ESULTS
retreatment with parecoxib (n  6) nearly doubled shear
tress-induced platelet aggregation (Fig. 2A). The amount
f aggregation during the first 10 min after pump start was
6.9  5.3  103 nPA/ml, compared with 14.3  3.2 
03 nPA/ml in control rats (n  6; p  0.0003). Plasma
-keto-PGF1, the stabile metabolite of PGI2, was reduced
rom 100 25 pg/ml to 36 11 pg/ml (p 0.0001) (Fig. 3).
nhanced platelet aggregation was also found after pretreat-
ent with NS-398 (19.4  4.6  103 nPA/ml, n  3, p 
.04 vs. control) and, as shown in Figure 2B, after non-
elective COX-2-inhibition with high-dose aspirin (20.9 
.7 103 nPA/ml; n 6, p 0.02 vs. control). In contrast,
ow-dose aspirin reduced platelet aggregation (9.7  3.5 
03 nPA/ml; n  6, p  0.01 vs. control) (Fig. 2B).
Platelet aggregation also affects downstream vascular
esistance in the extracorporeally perfused hind limb. Under
ontrol conditions, pump-induced platelet aggregation
auses a triphasic change of vascular resistance: a short
nitial decline is followed by a 4- to 5-min lasting rise and
long-lasting fall (Fig. 4). The maximal rise in vascular
esistance (from 64  11 mm Hg/ml/min to 89  16 mmigure 2. Enhancement of pump-induced platelet aggregation by parecoxib (A
latelet aggregation by low-dose aspirin (B).g/ml/min) was observed after 2 min of pump-induced
latelet aggregation and resulted from an increase in mean
emoral artery pressure (from 127 16 mm Hg to 173 32
m Hg) at unaltered mean femoral artery flow (2.0  0.4
l/min). This triphasic response was previously shown to be
elated to increasing and decreasing plasma concentrations
f serotonin released from activated platelets (12). The
onstrictive phase of this response was significantly rein-
orced by parecoxib (p  0.04) (Fig. 4A) and by high-dose
spirin (p  0.03) (Fig. 4B), consistent with enhanced
pstream platelet aggregation and increased release of sero-
onin. Low-dose aspirin had no significant effect (Fig. 4B).
Excess aggregation induced by parecoxib could not be
orrected by co-administration of low-dose aspirin (Fig.
A). The amount of aggregation in this condition (25.4 
.5  103 nPA/ml, n  6) did not significantly differ from
hat with parecoxib alone (p  0.32) or from that with
igh-dose aspirin alone (p  0.19). The enhancing effect of
OX-2 inhibition was, however, neutralized by clopidogrel
n a dose as low as 1 mg/kg (Fig. 5B; 13.2  1.4  103
PA/ml; n  6, p  0.48 vs. control). Higher doses of
lopidogrel caused further reduction of shear-induced plate-
et aggregation (5.5  0.4  103 nPa/ml at 5 mg/kg [n  2]
nd 4.9  0.1  103 nPa/ml at 25 mg/kg [n  2]), and
dose of 50 mg/kg prevented pump-induced aggregation
1.2  1.4  103 nPa/ml, n  4).
igure 3. Parecoxib (20 mg/kg) reduces the plasma level of the prostacyclin
PGI2) metabolite 6-keto-prostaglandin F1 from 100 25 pg/ml (n 7)
o 36  11 pg/ml (n  15). *p  0.0001.) and by high-dose aspirin (B), as well as attenuation of pump-induced
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COX-2 Inhibitors Enhance Platelet Aggregation August 15, 2006:817–23Also the parecoxib-induced increase of vasoconstriction
ould, similarly to the enhancement of platelet aggregation,
e prevented by pretreatment with low-dose clopidogrel
1 mg/kg) (Fig. 4A).
ISCUSSION
n an experimental rat model of arterial bypass with focal
arrowing and high shear stress, the present study observed:
) enhanced platelet aggregation and vasoconstriction of the
ownstream vascular bed after pre-treatment with the se-
ective COX-2 inhibitors parecoxib and NS-398; 2) en-
anced or reduced platelet aggregation with, respectively,
igh- or low-dose aspirin; and 3) correction of the
arecoxib-induced enhancement of platelet aggregation by
o-administration of low-dose clopidogrel but not by
o-administration of low-dose aspirin.
OX-2 inhibitors and platelet aggregation. Prostacyclin
s known as one of the strongest platelet inhibitors, espe-
ially in high shear stress conditions (10). Binding of PGI2
o its platelet receptors increases cyclic adenosine mono-
hosphate (18), which reduces cytosolic calcium, an essen-
ial mediator of shear stress-induced platelet aggregation
igure 4. Changes of vascular resistance in the extracorporeally perfused
riphasic response to pump perfusion is observed, consisting of a very sh
asodilation. Both parecoxib (parec) (A) and high-dose aspirin (B) sign
espectively). Pretreatment with a low dose of clopidogrel (clop) prevented
ailed to induce significant changes from control (B).
igure 5. Enhancement of pump-induced platelet aggregation by parecoxib
A) but is neutralized with a low dose (1 mg/kg) of clopidogrel (clop) (B); higher
revented (50 mg/kg) platelet aggregation.19) (Fig. 6). The enhanced shear stress-induced platelet
ggregation after pretreatment with COX-2 inhibitors ob-
erved in the present study is explained by reduced binding
f PGI2 to platelet receptors because of lower plasma PGI2
oncentrations. Although endothelial release of PGI2 is
ften presumed to occur only during inflammation, a
ontinuous basal release of PGI2 has also been observed,
specially in the lungs (20,21). Moncada and Vane (22)
herefore hypothesized that even under basal conditions
latelet activation is continuously depressed by endogenous
GI2. The short half-life of PGI2 and the use of in vitro
ggregometry made it difficult to prove this hypothesis.
ith in vivo aggregometry, the present study shows that
asal PGI2 formation can be reduced by selective COX-2
nhibitors and that this reduction can importantly enhance
hear stress-induced platelet aggregation. Prostacyclin also
timulates disaggregation of formed platelet aggregates (23),
nd COX-2 inhibitors can therefore elongate the lifespan of
he aggregates. Furthermore, in the presence of upstream
latelet aggregation, COX-2 inhibitors enhance the risk of
schemic organ damage by diminishing local tissue perfusion
ecause of an accentuated rise of vascular resistance. This
limb during a 10-min pump perfusion run. Under control conditions a
ilation, followed by 4 to 5 min of vasoconstriction and a longer-lasting
tly reinforced the vasoconstrictive response (p  0.04 and p  0.03,
arecoxib-induced reinforcement of vasoconstriction (A). Low-dose aspirin
c) is not significantly altered by co-administration of low-dose aspirin (asp)hind
ort d
ifican
the p(Pare
doses of clopidogrel progressively reduced (5 and 25 mg/kg) or completely
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August 15, 2006:817–23 COX-2 Inhibitors Enhance Platelet Aggregationasoconstrictive response to upstream platelet aggregation
as previously shown to result from serotonin released by
latelets (12).
Increased platelet reactivity after COX-2 inhibition was
reviously suggested by shortened vessel occlusion times in
nimals with endothelial arterial injury (24) and by pro-
onged duration of distal embolization after arteriolar punc-
ure (25). Even in intact arterioles, PGI2 was important to
revent rolling or deposition of platelets (26,27). The
resent study did not expose platelets to damaged endothe-
ium but subjected them to high shear stress as encountered
n tight arterial stenoses. High shear stress induces agonist-
ndependent platelet aggregation (Fig. 6). It triggers platelet
ctivation by deformation of platelets and by conformational
hanges in von Willebrand factor (vWf), a large plasma
ultimer that exposes its A1-domain to bind to platelet
lycoprotein (GP) Ib receptors (28–30). This binding
riggers intracellular calcium mobilization and subsequent
elease of ADP and other substances from dense- and
lpha-granules. Adenosine diphosphate binds to P2Y1 re-
eptors on neighboring platelets and on the original platelet,
igure 6. Proposed role of cyclooxygenase (COX)-2 and COX-1 in shear
ontrol of COX-2–induced endothelial prostacyclin (PGI2) that decrease
cAMP). Shear stress starts the sequence of events by “unrolling” the plas
f the vWf A1-domain to platelet glycoprotein (GP) Ib receptors triggers in
ADP) from dense granules and vWf from the alpha-granules. Adenosine d
latelets to activate GP IIb/IIIa receptors that bind fibrinogen and
TXA2)-formation reinforces aggregation at low or moderate shear stre
ggregation can be prevented by blockade (R) of P2Y12-receptors with clohere it further enhances calcium mobilization. Adenosine aiphosphate also binds to P2Y12 receptors, which activate
latelet GP IIb/IIIa receptors. Activation of GP IIb/IIIa
eceptors leads to attachment of adhesive proteins such as
brinogen and vWf (31,32). This is essential for formation
f platelet aggregates and is further potentiated by release of
Wf from alpha-granules (28).
igh- versus low-dose aspirin and platelet aggregation.
he present study observed enhanced platelet aggregation
fter non-selective COX inhibition with high-dose aspirin.
n contrast, low-dose aspirin reduced platelet aggregation
ut was unable to prevent it (Fig. 2B). The reduction was
ost likely caused by COX-1 inhibition in platelets. Be-
ause aspirin blocks COX-1 irreversibly and because plate-
ets are anucleate cells that cannot restore COX-1 by de
ovo protein synthesis, a small amount of aspirin can
rofoundly reduce thromboxane production of platelets. In
ontrast, nucleated endothelial cells can perform protein
esynthesis and resume COX-2 mediated PGI2 production
hortly after administration of low-dose aspirin. As indi-
ated in Figure 6, thromboxane-A2 derived from COX-1
einforces shear stress-induced platelet aggregation. Block-
s-induced platelet aggregation. Platelet aggregability is under continuous
ium (Ca2) by increasing the levels of cyclic adenosine monophosphate
n Willebrand factor (vWf) and possibly by platelet deformation. Binding
llular Ca2 mobilization with subsequent release of adenosine diphosphate
phate stimulates 5=-diphosphate (P2Y12)-receptors on the same and other
thereby causing aggregation. Platelet COX-1–induced thromboxane
t not at high shear stress (dotted lines). Shear stress-induced platelet
rel.stres
s calc
ma vo
trace
iphos
vWf,de of thromboxane-A2 formation with low-dose aspirin
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COX-2 Inhibitors Enhance Platelet Aggregation August 15, 2006:817–23oes, however, not importantly diminish aggregation when
hear stress exceeds 100 dynes/cm2 (33,34). At high shear
tress the vWf becomes more important, and its release
rom alpha-granules is not inhibited by aspirin (35). This
xplains the limited efficacy of low-dose aspirin in the
resent experimental model, in which shear stress exceeds
00 dynes/cm2.
revention of parecoxib-enhanced platelet aggregation
ith low-dose clopidogrel but not with low-dose aspirin.
lthough low-dose aspirin significantly reduced shear
tress-induced platelet aggregation, co-administration of
arecoxib with low-dose aspirin did not modify the
arecoxib-induced enhancement of aggregation. In contrast,
his enhancement was prevented with a dose of 1 mg/kg
lopidogrel. Higher doses of clopidogrel (5 and 25 mg/kg)
esulted in further inhibition of aggregation, and a dose of
0 mg/kg completely abolished roller pump-induced plate-
et aggregation. Clopidogrel does not interfere with the
roduction of thromboxane-A2 but blocks platelet ADP-
2Y12 receptors. Activation of these receptors is one of the
nal links in the cascade of shear-induced platelet aggrega-
ion (Fig. 6), and clopidogrel is known to effectively inter-
upt this mechanism in vitro (28,36) and in vivo (13).
Because in the present experiments low-dose clopidogrel
ffectively prevented parecoxib-induced enhancement of
hear stress-induced platelet aggregation, clopidogrel could
lso be useful in patients with pre-existing cardiovascular
isease to prevent cardiovascular complications when using
OX-2 inhibitors. An estimate of the clinical oral dose of
lopidogrel that could achieve an effect on shear stress-induced
latelet aggregation comparable to the 1 mg/kg intravenous
ose effective in rats can only be inferred from in vitro
DP-induced platelet aggregation. In vitro ADP-induced
latelet aggregation has indeed been studied both in rats
nd in humans, in contrast to in vivo shear stress-induced
latelet aggregation, which has only been studied in rats. A
imilar 50% inhibition of in vitro ADP-induced platelet
ggregation is observed in rats after an intravenous dose of
mg/kg (37) and in humans after an oral dose of 5 mg/kg
38,39). Assuming the inhibitory effect of clopidogrel on
latelet aggregation to be similar for aggregation induced in
itro by ADP and in vivo by shear stress, the intravenous
ose of 1 mg/kg effective in the present rat experiments
ould correspond to a clinical oral dose of 1 mg/kg.
We conclude that both selective COX-2 inhibition with
arecoxib or NS-398 and non-selective inhibition with
igh-dose aspirin enhance high shear stress-induced
latelet aggregation. This enhancement can be prevented
y a low dose of clopidogrel but not by low-dose aspirin.
o-administration of low-dose clopidogrel might therefore
nable patients with cardiovascular disease to benefit from
OX-2 inhibition without augmenting cardiovascular risk.
cknowledgment
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f 6-keto-PGF1.
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